Treatment and prevention of respiratory syncytial virus lower respiratory tract infection. Long-term effects on respiratory outcomes.
Simoes
E A
EA
Section of Infectious Diseases, Department of Pediatrics, University of Colorado School of Medicine and Children's Hospital, Denver, Colorado 80218, USA. eric.simoes@uchsc.edu
D000280:Administration, Inhalation; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000627:therapeutic use; D001249:Asthma / Q000517:prevention & control* / Q000821:virology*; D002648:Child; D002675:Child, Preschool; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007223:Infant; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000628:therapy*; D012141:Respiratory Tract Infections / Q000628:therapy* / Q000821:virology*; D013256:Steroids
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D016756:Immunoglobulins, Intravenous; D013256:Steroids; D000069455:Palivizumab